Bill > HR8370

This bill, titled the "Dietary Supplement Listing Act of 2026," aims to increase transparency and information availability for dietary supplements by amending the Federal Food, Drug, and Cosmetic Act. The core provision requires manufacturers, packers, or distributors of dietary supplements (referred to as "responsible persons") to submit detailed information about each product to the Secretary of Health and Human Services (the Secretary), which is the Food and Drug Administration (FDA). This information includes the supplement's name, brand name, all ingredients with their amounts per serving (with proprietary blend ingredient amounts kept confidential), daily values if applicable, the number of servings per container, directions for use, warnings, allergen statements, the form of the supplement (e.g., tablet, capsule), and any health-related claims made. Foreign entities must designate a United States agent to handle these submissions. The Secretary will assign a unique product listing number to each supplement, which must appear on the product's label starting two years after the bill's enactment. Existing supplements on the market before January 1, 2027, will have a specified period to be listed, while new supplements must be listed at the time of introduction into interstate commerce. The Secretary will also establish a publicly searchable electronic database containing most of this submitted information, excluding certain confidential details. Failure to comply with these listing requirements will result in the dietary supplement being considered "misbranded." The bill also authorizes appropriations for fiscal years 2026 through 2030 to carry out these new provisions.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/8370/all-info